A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease

Purpose: To determine whether reproxalap, a novel reactive aldehyde species (RASP) inhibitor, is safe and effective for the treatment of the signs and symptoms of dry eye disease (DED). Methods: In a randomized double-masked parallel-group Phase 2a trial of 3 topical ocular reproxalap formulations (...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, David, Sheppard, John, Brady, Todd C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106247/
https://www.ncbi.nlm.nih.gov/pubmed/33450164
http://dx.doi.org/10.1089/jop.2020.0087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106247/
https://www.ncbi.nlm.nih.gov/pubmed/33450164
http://dx.doi.org/10.1089/jop.2020.0087

Ejemplares similares